Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open‐Label, Noninferiority Study (PARASOL Study)
The Journal of Clinical Hypertension · 2025
DOI: 10.1111/jch.14938 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Clinical Hypertension, 2025. Verfasst von Koichi Yamamoto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Aminobutyrates, Amlodipine, Amlodipine, Valsartan Drug Combination, Antihypertensive Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharma K.K..
Abstract (Originalsprache)
Sacubitril/valsartan, an angiotensin receptor‐neprilysin inhibitor, has demonstrated a superior blood pressure‐lowering effect compared with renin‐angiotensin system inhibitors in several clinical trials. However, there has been no available evidence on the comparison between sacubitril/valsartan and calcium channel blockers (CCBs), a well‐established class of antihypertensive drugs. In this open‐label, multicenter study, we aimed to demonstrate the efficacy and safety of sacubitril/valsartan versus amlodipine, one of the most widely used CCBs, after 8 weeks of treatment. A total of 359 Japanese patients with essential hypertension (office systolic blood pressure [SBP] ≥ 150 to < 180 mmHg), aged 18–79, were randomly assigned to receive either once‐daily sacubitril/valsartan 200 mg or once‐daily amlodipine 5 mg in a 1:1 allocation ratio. The primary endpoint was the noninferiority of sacubitril/valsartan compared with amlodipine in mean change in 24‐h SBP from baseline to Week 8, followed by a significance test as a secondary endpoint analysis. The mean change in 24‐h SBP in sacubitril/valsartan was noninferior to that in amlodipine (between‐treatment difference −0.62 mmHg [95% confidential interval: −3.23 to 1.98; p = 0.003 for noninferiority; independent t ‐test with noninferiority margin 3.0 mmHg]), with no significant difference observed ( p = 0.637). There was no significant difference in the incidence of adverse events (AEs). These results suggested that the blood pressure‐lowering effect of sacubitril/valsartan is comparable to that of amlodipine, with no marked differences in tolerability between the two groups. Sacubitril/valsartan, a potent antihypertensive drug comparable to amlodipine, is expected to improve blood pressure control in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
- Medical Affairs, Novartis Pharma K.K., Tokyo, Japan.
- Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
- Osaka Rosai Hospital, Osaka, Japan.
ORCID-Profile: Koichi Yamamoto, Daisuke Yarimizu, Ayano Shimanishi, Shunsuke Eguchi, Kazuma Iekushi, Yoichi Takami, Yoichi Nozato, Kazuomi Kario, Hiromi Rakugi
Förderung
- Novartis Pharma K.K.
Zitieren
APA
Yamamoto, K., Yarimizu, D., Shimanishi, A., Eguchi, S., Iekushi, K., Takami, Y., Nozato, Y., Kario, K., & Rakugi, H. (2025). Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open‐Label, Noninferiority Study (PARASOL Study). The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.14938
Vancouver
Yamamoto K, Yarimizu D, Shimanishi A, Eguchi S, Iekushi K, Takami Y, et al. Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open‐Label, Noninferiority Study (PARASOL Study). The Journal of Clinical Hypertension. 2025. doi:10.1111/jch.14938
BibTeX
@article{Yamamoto2025,
author = {Yamamoto, Koichi and Yarimizu, Daisuke and Shimanishi, Ayano and Eguchi, Shunsuke and Iekushi, Kazuma and Takami, Yoichi and Nozato, Yoichi and Kario, Kazuomi and Rakugi, Hiromi},
title = {Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open‐Label, Noninferiority Study (PARASOL Study)},
journal = {The Journal of Clinical Hypertension},
year = {2025},
doi = {10.1111/jch.14938}
}
EUVIMED